Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77555, USA.
J Biol Chem. 2011 Jul 8;286(27):24089-100. doi: 10.1074/jbc.M111.219733. Epub 2011 May 16.
The development of intratumoral hypoxia, a hallmark of rapidly progressing solid tumors, renders tumor cells resistant to chemotherapy and radiation therapy. We have recently shown that inhibition of aldose reductase (AR), an enzyme that catalyzes the reduction of lipid aldehydes and their glutathione conjugates, prevents human colon cancer cell growth in culture as well as in nude mouse xenografts by inhibiting the NF-κB-dependent activation of oxidative stress-mediated inflammatory and carcinogenic markers. However, the role of AR in mediating hypoxic stress signals is not known. We therefore investigated the molecular mechanisms by which AR inhibition prevents the hypoxia-induced human colon cancer cells growth and invasion. Our results indicate that AR inhibition by the pharmacological inhibitor fidarestat or ablation by AR-specific siRNA prevents hypoxia-induced proliferation of HT29, SW480, and Caco-2 colon cancer cells. Furthermore, hypoxia-induced increase in the level of HIF-1α in colon cancer cells was significantly decreased by AR inhibition. During hypoxic conditions, treatment of HT29 cells with the AR inhibitor fidarestat significantly decreased the expression of vascular endothelial growth factor, a down target of HIF-1α, at both mRNA and protein levels and also prevented the activation of PI3K/AKT, GSK3β, Snail, and lysyl oxidase. Furthermore, inhibition of hypoxia-induced HIF-1α protein accumulation by AR inhibition was abolished in the presence of MG132, a potent inhibitor of the 26 S proteasome. In addition, AR inhibition also prevented the hypoxia-induced inflammatory molecules such as Cox-2 and PGE2 and expression of extracellular matrix proteins such as MMP2, vimentin, uPAR, and lysyl oxidase 2. In conclusion, our results indicate that AR mediates hypoxic signals, leading to tumor progression and invasion.
肿瘤内部缺氧的发展是快速进展的实体瘤的一个标志,使肿瘤细胞对化疗和放疗产生抗性。我们最近表明,抑制醛糖还原酶 (AR),一种催化脂质醛及其谷胱甘肽缀合物还原的酶,可以通过抑制 NF-κB 依赖性氧化应激介导的炎症和致癌标志物的激活,防止人结肠癌细胞在培养中和裸鼠异种移植物中的生长。然而,AR 在介导低氧应激信号中的作用尚不清楚。因此,我们研究了 AR 抑制防止缺氧诱导的人结肠癌细胞生长和侵袭的分子机制。我们的结果表明,通过药理学抑制剂 fidarestat 或 AR 特异性 siRNA 抑制 AR 可防止 HT29、SW480 和 Caco-2 结肠癌细胞的缺氧诱导增殖。此外,AR 抑制显著降低了缺氧诱导的结肠癌细胞中 HIF-1α 水平的增加。在缺氧条件下,用 AR 抑制剂 fidarestat 处理 HT29 细胞可显著降低血管内皮生长因子(HIF-1α 的下游靶标)的表达水平,无论是在 mRNA 还是蛋白水平,还可阻止 PI3K/AKT、GSK3β、Snail 和赖氨酰氧化酶的激活。此外,在存在 26S 蛋白酶体强效抑制剂 MG132 的情况下,AR 抑制对缺氧诱导的 HIF-1α 蛋白积累的抑制作用被消除。此外,AR 抑制还可防止缺氧诱导的 COX-2 和 PGE2 等炎症分子以及 MMP2、波形蛋白、uPAR 和赖氨酰氧化酶 2 等细胞外基质蛋白的表达。总之,我们的结果表明,AR 介导了缺氧信号,导致肿瘤的进展和侵袭。